# NCT06567743 (NCT06567743)

> Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06567743
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: CG Oncology, Inc.
- Conditions: High-Risk Non-Muscle-Invasive Bladder Cancer
- Interventions: Cretostimogene Grenadenorepvec
- Enrollment: 325
- Primary outcome: Cohort A (Arm 1 and 2): Complete response rate
- Primary outcome: Cohort A (Arm 3): High- Grade Event-Free Survival
- Primary outcome: Cohort B (Arm 1): Complete response rate
- Primary outcome: Cohort B (Arm 2): High-Grade Event-Free Survival
- Primary outcome: Cohort CX (Arms 1 and 2): High-Grade Event-Free Survival
- Primary outcome: Cohort CX (Arms 1 and 2): Safety

## Commentary we found

- YouTube: 4
- X threads: 4
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06567743

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06567743", "email": "<work email>"}; the inbox owner confirms by the emailed link.